CAMBRIDGE, Mass.

马萨诸塞州剑桥

,

，

July 30, 2026

2026年7月30日

/PRNewswire/ -- Apnimed, Inc. ('Apnimed'), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a price to the public of $16.00 per share.

/美通社/ -- Apnimed, Inc.（“Apnimed”）是一家处于后期临床阶段的制药公司，致力于发现、开发和商业化针对睡眠相关呼吸疾病神经生物学的新型口服疗法。该公司今日宣布，其扩大规模的首次公开发行（IPO）已定价，发行12,000,000股普通股，每股公开发行价格为16.00美元。

In addition, Apnimed has granted the underwriters a 30-day option to buy an additional 1,800,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions..

此外，Apnimed已授予承销商一项为期30天的选择权，可按首次公开发行价格扣除承销折扣和佣金后的金额，额外购买1,800,000股其普通股。

Apnimed common stock is expected to begin trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol 'APMD'. The offering is expected to close on or about August 3, 2026, subject to the satisfaction of customary closing conditions.

Apnimed的普通股预计将于2026年7月31日在纳斯达克全球精选市场开始交易，股票代码为“APMD”。本次发行预计将于2026年8月3日或前后完成，前提是满足惯常的交割条件。

BofA Securities, Evercore ISI, Cantor and LifeSci Capital are acting as joint book-running managers for the offering.

美国银行证券、Evercore ISI、Cantor和LifeSci Capital担任此次发行的联席账簿管理人。

The gross proceeds to Apnimed from the initial public offering, before deducting underwriting discounts and commissions and offering expenses payable by Apnimed, are expected to be $192 million, excluding any exercise of the underwriters' option to purchase additional shares of common stock. All of the shares of common stock are being offered by Apnimed..

在不扣除承销折扣、佣金以及由Apnimed支付的发行费用的情况下，Apnimed从首次公开募股中获得的总收益预计为1.92亿美元，此金额未包含承销商行使额外购买普通股选择权的任何部分。所有普通股均由Apnimed发行。

Registration statements relating to the offering have been filed with the Securities and Exchange Commission (the 'SEC') and became effective on July 30, 2026. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from the SEC's website at .

与本次发行相关的注册声明已提交至美国证券交易委员会（简称“SEC”），并于2026年7月30日生效。本次发行仅通过构成上述生效注册声明一部分的招股说明书进行。最终招股说明书的副本在可供获取时，可从美国证券交易委员会网站获取。

www.sec.gov

www.sec.gov

or from: BofA Securities, Inc., Attn: Prospectus Department, 201 North Tryon Street, Charlotte, NC 28255-0001, email:

或寄至：美国银行证券有限公司，收件人：招股说明书部门，地址：北卡罗来纳州夏洛特市北特里昂街201号，邮编28255-0001，电子邮件：

[email protected]

[email protected]

; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, telephone: (888) 474-0200, email:

Evercore Group L.L.C.，收件人：股权资本市场部，地址：纽约州纽约市东52街55号35层，邮编10055，电话：(888) 474-0200，电子邮件：

[email protected]

[email protected]

; or Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, New York 10022, or by email at

；或寄至 Cantor Fitzgerald & Co.，收件人：股权资本市场部，地址：110 E. 59th Street, 6th Floor, New York, New York 10022；或通过电子邮件发送至

[email protected]

[email protected]

.

。

This press release shall not constitute an offer to sell or solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售这些证券的要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，若根据该州或司法管辖区的证券法，在注册或资格认定之前进行此类要约、邀请或销售属违法行为，则不得在该州或司法管辖区销售这些证券。

About

关于

Apnimed

阿普尼梅德

Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with obstructive sleep apnea (OSA).

Apnimed 是一家处于临床后期阶段的制药公司，致力于发现、开发和商业化新型口服疗法，以应对与睡眠相关的呼吸疾病的神经生物学机制。我们相信，每日一次夜间服用的口服药物的推出，有望扩大阻塞性睡眠呼吸暂停（OSA）患者的诊断率和治疗覆盖范围。

We believe that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment and help more people get the oxygen and restorative sleep needed to thrive..

我们相信，拥有多种作用机制不同的药物将有助于更全面地应对阻塞性睡眠呼吸暂停（OSA）疾病病理生理学的异质性，从而使OSA患者受益。Apnimed展望一个新时代：新型口服疗法将简化干预措施，扩大诊断和治疗的覆盖范围，帮助更多人获得维持健康所需的氧气和恢复性睡眠。

Based in Cambridge, Massachusetts, Apnimed is advancing its product candidate, AD109, designed to improve oxygenation in individuals living with OSA. If approved, we believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries.

Apnimed 总部位于马萨诸塞州剑桥市，正在推进其产品候选药物 AD109 的研发，该药物旨在改善阻塞性睡眠呼吸暂停（OSA）患者的氧合状况。我们认为，如果获得批准，AD109 有望成为 OSA 新型口服治疗范式的催化剂，而历史上 OSA 的治疗一直局限于笨重的设备或侵入性手术。

AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Apnimed's New Drug Application for AD109 was assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 28, 2027..

AD109已完成两项用于治疗轻度、中度和重度阻塞性睡眠呼吸暂停（OSA）的III期临床试验。Apnimed公司提交的AD109新药申请已获《处方药用户费法案》（PDUFA）设定的目标日期为2027年2月28日。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release includes certain disclosures that contain 'forward-looking statements,' including, without limitation, statements regarding Apnimed's expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering.

本新闻稿包含某些披露信息，其中含有“前瞻性陈述”，包括但不限于关于Apnimed对其股份在纳斯达克全球精选市场开始交易的预期、发行的完成及收盘时间以及预计从发行中获得的总收益的陈述。

Forward-looking statements are based on Apnimed's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development.

前瞻性陈述基于Apnimed当前的预期，并受到难以预测的固有不确定性、风险和假设的影响。可能导致实际结果出现差异的因素包括但不限于：与满足惯例交割条件和完成发行相关的风险与不确定性，以及生物制药产品开发中固有的风险。

These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' section of the final prospectus related to the offering to be filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Apnimed undertakes no duty to update such information except as required under applicable law..

上述及其他风险和不确定性在向美国证券交易委员会（SEC）提交的与本次发行相关的最终招股说明书的“风险因素”章节中有更充分的描述。本公告中包含的前瞻性陈述仅反映截至本公告发布之日的情况，除非适用法律另有要求，Apnimed 不承担更新此类信息的义务。

Media Contact:

媒体联系人：

[email protected]

[email protected]

Investor Contact:

投资者联系：

[email protected]

[email protected]

SOURCE Apnimed, Inc.

来源：Apnimed, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示